PADCEV Support SolutionsSM offers Benefits Investigation (BI) assistance to evaluate a patient's insurance coveragea for PADCEVTM (enfortumab vedotin-ejfv).
After performing a BI, we will provide a Summary of Benefits that includes:
- The patient's insurance coverage for PADCEV
- Requirements for prior authorization or other coverage restrictions, if any
- Cost-sharing responsibilities, including the deductible, coinsurance or copayment, and out-of-pocket maximums
We will initiate a BI upon receipt of a completed Patient Enrollment Form.
Once BI is complete, we will send a Summary of Benefits.
PADCEV Support Solutions is a component of Astellas Pharma Support SolutionsSM.
aAstellas and Seattle Genetics do not guarantee third-party coverage, payment, or reimbursement for denied claims. Coverage and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Therefore, it is important that providers verify each patient’s insurance coverage prior to initiating therapy. Each healthcare provider is ultimately responsible for determining coverage for individual patients.
PADCEVTM is a trademark jointly owned by Agensys, Inc. and Seattle Genetics, Inc.